Skip to main content

Table 2 Administered agents/regimens and hazard ratio for overall survival

From: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review

Agents/regimens

No. of patients

No. of events, n (%)

HR

95 % CI

P value

Eribulin monotherapy

66

39 (59.1)

0.55

0.36–0.85

0.01*

Anthracycline-based regimen

136

120 (88.2)

1.35

1.01–1.82

0.04*

Paclitaxel monotherapy

138

103 (74.6)

1.14

0.85–1.52

0.38

Docetaxel monotherapy

79

72 (91.1)

1.30

0.95–1.79

0.10

Capecitabine monotherapy

120

100 (83.3)

0.89

0.66–1.20

0.43

Gemcitabine monotherapy

12

12 (83.3)

0.55

0.27–1.10

0.09

Vinorelbine monotherapy

37

37 (100.0)

1.15

0.76–1.73

0.51

Paclitaxel + bevacizumab

52

52 (57.7)

1.51

0.93–2.48

0.10

Docetaxel + capecitabine

30

30 (96.7)

1.13

0.74–1.73

0.57

Paclitaxel + gemcitabine

10

10 (100.0)

2.79

1.34–5.79

0.01*

  1. CI confidence interval, HR hazard ratio